295 related articles for article (PubMed ID: 9525616)
1. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
Tao T; Durbin AP; Whitehead SS; Davoodi F; Collins PL; Murphy BR
J Virol; 1998 Apr; 72(4):2955-61. PubMed ID: 9525616
[TBL] [Abstract][Full Text] [Related]
2. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
[TBL] [Abstract][Full Text] [Related]
3. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
Tao T; Skiadopoulos MH; Durbin AP; Davoodi F; Collins PL; Murphy BR
Vaccine; 1999 Mar; 17(9-10):1100-8. PubMed ID: 10195620
[TBL] [Abstract][Full Text] [Related]
4. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts.
Skiadopoulos MH; Tao T; Surman SR; Collins PL; Murphy BR
Vaccine; 1999 Oct; 18(5-6):503-10. PubMed ID: 10519940
[TBL] [Abstract][Full Text] [Related]
5. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
[TBL] [Abstract][Full Text] [Related]
6. Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone.
Tao T; Skiadopoulos MH; Davoodi F; Surman SR; Collins PL; Murphy BR
Vaccine; 2001 Jun; 19(27):3620-31. PubMed ID: 11395195
[TBL] [Abstract][Full Text] [Related]
7. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.
Durbin AP; Skiadopoulos MH; McAuliffe JM; Riggs JM; Surman SR; Collins PL; Murphy BR
J Virol; 2000 Aug; 74(15):6821-31. PubMed ID: 10888621
[TBL] [Abstract][Full Text] [Related]
8. Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes.
Skiadopoulos MH; Surman SR; Durbin AP; Collins PL; Murphy BR
Virology; 2000 Jun; 272(1):225-34. PubMed ID: 10873765
[TBL] [Abstract][Full Text] [Related]
9. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
[TBL] [Abstract][Full Text] [Related]
10. Chimeric bovine respiratory syncytial virus with attachment and fusion glycoproteins replaced by bovine parainfluenza virus type 3 hemagglutinin-neuraminidase and fusion proteins.
Stope MB; Karger A; Schmidt U; Buchholz UJ
J Virol; 2001 Oct; 75(19):9367-77. PubMed ID: 11533200
[TBL] [Abstract][Full Text] [Related]
11. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.
Schmidt AC; McAuliffe JM; Huang A; Surman SR; Bailly JE; Elkins WR; Collins PL; Murphy BR; Skiadopoulos MH
J Virol; 2000 Oct; 74(19):8922-9. PubMed ID: 10982335
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.
Skiadopoulos MH; Surman SR; Riggs JM; Orvell C; Collins PL; Murphy BR
Virology; 2002 May; 297(1):136-52. PubMed ID: 12083844
[TBL] [Abstract][Full Text] [Related]
13. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4.
Stewart-Jones GBE; Chuang GY; Xu K; Zhou T; Acharya P; Tsybovsky Y; Ou L; Zhang B; Fernandez-Rodriguez B; Gilardi V; Silacci-Fregni C; Beltramello M; Baxa U; Druz A; Kong WP; Thomas PV; Yang Y; Foulds KE; Todd JP; Wei H; Salazar AM; Scorpio DG; Carragher B; Potter CS; Corti D; Mascola JR; Lanzavecchia A; Kwong PD
Proc Natl Acad Sci U S A; 2018 Nov; 115(48):12265-12270. PubMed ID: 30420505
[TBL] [Abstract][Full Text] [Related]
15. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.
Spriggs MK; Murphy BR; Prince GA; Olmsted RA; Collins PL
J Virol; 1987 Nov; 61(11):3416-23. PubMed ID: 2822951
[TBL] [Abstract][Full Text] [Related]
16. Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells.
Nelson CL; Tang RS; Stillman EA
Vaccine; 2013 Aug; 31(36):3756-62. PubMed ID: 23623857
[TBL] [Abstract][Full Text] [Related]
17. Identification of regions on the hemagglutinin-neuraminidase protein of human parainfluenza virus type 2 important for promoting cell fusion.
Tsurudome M; Kawano M; Yuasa T; Tabata N; Nishio M; Komada H; Ito Y
Virology; 1995 Oct; 213(1):190-203. PubMed ID: 7483263
[TBL] [Abstract][Full Text] [Related]
18. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.
Tang RS; Schickli JH; MacPhail M; Fernandes F; Bicha L; Spaete J; Fouchier RA; Osterhaus AD; Spaete R; Haller AA
J Virol; 2003 Oct; 77(20):10819-28. PubMed ID: 14512532
[TBL] [Abstract][Full Text] [Related]
19. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity.
Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Vaccine; 2017 Dec; 35(51):7139-7146. PubMed ID: 29153777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
